These peptides have demonstrated a strong TGF-β inhibitory effect in animal models of liver and pulmonary fibrosis and hypertension (Ezquerro et al., 2003; Arribillaga et al., 2011; Baltanás et al., 2013). Here, TGFB1 is linked to pulmonary fibrosis.